Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia
Year: 2026
Type: article
Study design: Observational Study
Abstract: Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of B-cell ALL associated with poor response to induction chemotherapy, suboptimal measurable residual disease (MRD) clearance, and inferior survival outcomes compared to non-Phlike subtypes. We retrospectively analyzed 140 consecutive adult patients with Ph-like ALL treated at our institution. The median age was 33.5 years, and the majority harbored CRLF2 rearrangements (85%). IKZF1plus deletion and JAK mutations were identified in 26% and 37% of patients, respectively. The majority (75%) received pediatric-inspired regimens (PIR), which were associated with higher complete remission (CR) rates (p=0.034), reduced risk of relapse (p.
Source: Haematologica
Authors: Ibrahim Aldoss, Arthur Li, Diana Knobler, Vaibhav Agrawal, Hoda Pourhassan, Paul Koller, Tamer Othman, Monzr M. Al Malki, Amandeep Salhotra, Karamjeet Sandhu, Haris Ali, Ahmed Aribi, Amanda Blackmon, Brian Ball, Idoroenyi Amanam, Salman Otoukesh, Rick Lin, Julio C. Alvarenga Thiebaud, Sunmin Park, Samer Khaled, Jose Tinajero, Dat Ngo, Zhaohui Gu, Lindsey Murphy, Yazeed Samara, Michelle Afkhami, Andrew Artz, Pamela Becker, Ryotaro Nakamura, Anthony Stein, Stephen Forman, Guido Marcucci, Vinod Pullarkat
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Award: Cancer Center Support Grant
OpenAlex ID: W7207615787